Acute inflammatory demyelinating polyneuropathy is set to dominate disease type at 63.0% share in 2026, followed by hospitals as likely to secure 51.0% share of end user in 2026. Adoption rests on coordinated neurologic assessment and cerebrospinal-fluid review. Inconclusive early findings and uneven specialist access form principal barriers.